CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

In a stark reflection of the challenges facing the biotech sector, Turnstone Biologics Corp. (TSBX) stock has tumbled to a 52-week low, reaching a price level of just $0.4. This latest price point ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Of the three, SOUN is performing the worst on a year-to-date basis, down 27.8% in 2025. This could be mostly due to ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Revenue for the fourth quarter and full year 2024 was $47.5 million and $179.0 million, respectively. The MRD business, which contributed 85% of revenue in the fourth quarter and 81% of revenue in the ...

FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and developme ...

Highlights,Bio-Rad Laboratories (BIO) drives innovation in life sciences and clinical diagnostics with a diversified product ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

On the positive side, the company has recently reported a 27% increase in Medicare Advantage members, surpassing 100,000 ...